2026-01-19 - Analysis Report
# Financial Report for Johnson & Johnson (JNJ)

## Company Overview
Johnson & Johnson - 글로벌 헬스케어 및 제약 종합 그룹 (Global healthcare and pharmaceutical conglomerate)

## Return Rate Comparison
- Return rate of the review stock: 17.20%
- Return rate of the comparison stock (VOO): 82.54%
- Divergence: 
  • Max: N/A
  • Min: N/A
  • Current: N/A
  • Relative divergence: Current position: N/A

Analysis: The review stock's return rate is significantly lower than the comparison stock, indicating a potential divergence in performance.

## Alpha, Beta Analysis
### | Year | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | -5.0% | 10.9% | -5.0% | 0.7 | 310.9B |
| 2017-2019  | -2.0% | 10.9% | -11.0% | 0.7 | 351.4B |
| 2018-2020  | 10.0% | 10.9% | -11.0% | 0.7 | 379.2B |
| 2019-2021  | 29.0% | 10.2% | -9.0% | 0.6 | 412.2B |
| 2020-2022  | 20.0% | 12.5% | 10.0% | 0.5 | 425.6B |
| 2021-2023  | -5.0% | 13.6% | -21.0% | 0.3 | 377.6B |
| 2022-2024  | -27.0% | 13.6% | -53.0% | 0.2 | 348.4B |
| 2023-2025  | 3.0% | 13.6% | -46.0% | 0.1 | 498.6B |

Analysis: The review stock's CAGR and MDD show fluctuating performance across the periods, while Alpha and Beta remain relatively stable.

## Recent Stock Price Fluctuations
- Close: $218.66 
- Last-market: $218.66 - $219.57 (-0.41%)
- 5-day SMA: $216.03
- 20-day SMA: $208.94
- 60-day SMA: $201.95

Analysis: The stock price is fluctuating, with a slight decline in the last market, and the 5-day SMA is slightly lower than the 20-day and 60-day SMA.

## RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence
- Market Risk Indicator (MRI): 0.80 (High Investment Recommended)
- RSI: 70.76
- PPO: 0.54
- Hybrid Signal: Buy (Cash 21%)
- Risk Level: Medium (MRI 0.80)
- Recent (20 days) relative divergence change: 0.0 (flat)
- 7-day Rank change: 0 (flat)
- 7-day Dynamic Expected Return change: 0.0 (flat)

Analysis: The hybrid signal recommends a buy, and the risk level is medium, with the market risk indicator at a suitable level.

## Expected Return
Expected Return: N/A

## Recent News & Significant Events
- [2026-01-13] Here’s What Lifted Johnson & Johnson (JNJ) in Q4 - Yahoo Finance
- [2025-12-30] More Upside For JNJ Stock In 2026? - Forbes
- [2026-01-16] Johnson & Johnson Stock Capital Return Hits $159 Bil - Trefis
- [2026-01-18] Jim Cramer says: "J&J deserves to be going higher, but not at this speed, not at this pace" - MSN
- [2026-01-18] Conning Inc. Has $33.13 Million Position in Johnson & Johnson $JNJ - MarketBeat
- [2026-01-13] Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court - Reuters

Analysis: The recent news and events suggest mixed sentiment with some analysts recommending further upside and others cautioning on the pace of the stock's growth.

## Analyst Opinions
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.16 (~Buy)
- Opinions: 24
- Target Price (avg/high/low): 212.00 / 240.00 / 155.00

## Recent Earnings Analysis
### | Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-22 | 2.14 | 23.99 B$ |
| 2025-07-24 | 2.3 | 23.74 B$ |
| 2025-04-23 | 4.57 | 21.89 B$ |
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2025-10-22 | 1.12 | 22.47 B$ |

Analysis: The quarterly EPS and revenue show fluctuating performance, with a recent surge in EPS and a slight decline in revenue.

## Financial Information
### Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |

Analysis: The revenue and profit margin show a fluctuating trend, with the profit margin ranging from 66.40% to 69.56%.

### Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |

Analysis: The equity and ROE (Return on Equity) show fluctuating performance, with a recent surge in ROE.

## Comprehensive Analysis
- The return rate of the review stock is significantly lower than the comparison stock.
- The Alpha, Beta analysis shows fluctuating performance across the periods, while Alpha and Beta remain relatively stable.
- The recent stock price fluctuations show a slight decline, with the 5-day SMA slightly lower than the 20-day and 60-day SMA.
- The RSI, PPO index indicators, and Delta_Previous_Relative_Divergence show a hybrid signal recommending a buy, with a medium risk level.
- The recent news and events suggest mixed sentiment with some analysts recommending further upside and others cautioning on the pace of the stock's growth.
- The quarterly EPS and revenue show fluctuating performance, with a recent surge in EPS and a slight decline in revenue.
- The revenue and profit margin show a fluctuating trend, with the profit margin ranging from 66.40% to 69.56%.
- The equity and ROE show fluctuating performance, with a recent surge in ROE.

Overall, the comprehensive analysis suggests a mixed outlook for the review stock, with both positive and negative trends.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.